Share Price and Basic Stock Data
Last Updated: November 7, 2025, 10:53 pm
| PEG Ratio | 1.43 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Ambar Protein Industries Ltd operates in the edible oils and solvent extraction industry, with a current market capitalization of ₹175 Cr. The company’s share price stood at ₹305, reflecting a price-to-earnings (P/E) ratio of 21.8. Over the past fiscal years, Ambar reported fluctuating revenues, with sales recorded at ₹340 Cr in FY 2022, rising to ₹345 Cr in FY 2023, and expected to reach ₹421 Cr in FY 2025. However, the trailing twelve months (TTM) sales have shown a robust increase to ₹446 Cr, indicating a positive revenue trajectory. Quarterly sales displayed variability, with the highest being ₹94.92 Cr in December 2022 and a recent decline to ₹68.61 Cr in September 2023. This inconsistency suggests potential seasonality or market volatility impacting sales performance. The company’s operational performance is crucial, and the recorded operating profit margin (OPM) remained low at 1.82%, which is below typical sector norms, indicating a need for improved cost management strategies to enhance profitability.
Profitability and Efficiency Metrics
Ambar Protein Industries’ profitability metrics reveal a mixed performance over time. The net profit for FY 2023 was reported at ₹9 Cr, translating to an earnings per share (EPS) of ₹4.89. This figure rose significantly to ₹10 Cr in FY 2025, with an EPS projected at ₹16.78, indicating a strong recovery and growth in profitability. The company’s return on equity (ROE) stood at 32.3%, showcasing effective utilization of shareholder funds, while the return on capital employed (ROCE) was reported at 27.5%, suggesting efficient capital management. However, the operating profit margin (OPM) has been inconsistent, with a peak of 4.46% in December 2023 and a decline to -0.84% in March 2024, highlighting volatility in operational efficiency. The cash conversion cycle (CCC) averaged 34 days, which is relatively efficient compared to sector averages, indicating effective inventory and receivables management. Nonetheless, the net profit margin, which stood at 2.28% in FY 2025, remains low, suggesting room for improvement in overall profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ambar Protein Industries reflects a cautious approach to financial management. The company reported total borrowings of ₹26 Cr against reserves of ₹29 Cr, indicating a manageable debt level relative to equity. The interest coverage ratio (ICR) stood robust at 7.32x, signaling strong ability to service debt obligations. The current ratio of 1.45x indicates sufficient liquidity to cover short-term liabilities, while the quick ratio of 0.83x suggests some vulnerability in immediate cash flow management. The price-to-book value (P/BV) ratio is reported at 3.36x, which is relatively high, indicating that the stock may be overvalued compared to its book value. Moreover, the asset turnover ratio of 6.39% indicates efficient use of assets to generate revenue. Overall, while the balance sheet shows strength in liquidity and debt management, the high P/BV ratio could be a concern for potential investors looking for undervalued opportunities.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ambar Protein Industries reflects significant promoter confidence, with promoters holding 71.48% of the shares as of September 2025. This stable ownership structure suggests a strong commitment from the founding members to the company’s long-term growth. The public shareholding stands at 28.51%, with the total number of shareholders increasing to 3,177, indicating growing interest among retail investors. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may suggest a gap in institutional confidence, which could impact stock liquidity and overall market perception. The gradual increase in promoter shareholding over the reporting periods, from 70.35% in December 2022 to the current level, reinforces a positive outlook on corporate governance and alignment of interests between management and shareholders. This pattern may instill confidence among existing and potential investors regarding the company’s strategic direction and governance practices.
Outlook, Risks, and Final Insight
Looking ahead, Ambar Protein Industries faces a mixed outlook characterized by both opportunities and challenges. The company’s ability to enhance its operating profit margins and stabilize sales will be crucial for sustaining growth. The strong ROE and ROCE ratios indicate effective management, but the low net profit margin and high P/BV ratio present risks that could deter potential investors. Furthermore, fluctuations in raw material costs and market demand are ongoing challenges in the edible oils sector. The company’s focus on improving operational efficiency, managing debt levels, and enhancing profitability metrics will be vital for maintaining investor confidence. If Ambar can leverage its strong promoter backing to navigate market volatility effectively and improve financial performance, it may position itself favorably for future growth. However, failure to address operational inefficiencies and maintain liquidity could pose significant risks to its financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ambar Protein Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 570 Cr. | 435 | 667/320 | 16.7 | 92.8 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 106 Cr. | 8.12 | 10.3/3.87 | 3.44 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 330 Cr. | 1.76 | 4.40/1.65 | 189 | 2.45 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 59.8 Cr. | 2.51 | 5.12/1.45 | 22.2 | 2.71 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 4,487 Cr. | 1,603 | 3,633/293 | 5,158 | 32.8 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 9,152.44 Cr | 192.43 | 340.73 | 35.62 | 0.17% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84.38 | 75.77 | 94.92 | 90.00 | 93.22 | 68.61 | 85.72 | 89.51 | 93.04 | 88.95 | 111.82 | 127.81 | 117.27 |
| Expenses | 81.92 | 74.30 | 92.42 | 89.17 | 90.62 | 67.04 | 81.90 | 90.26 | 90.10 | 84.72 | 107.00 | 124.02 | 115.13 |
| Operating Profit | 2.46 | 1.47 | 2.50 | 0.83 | 2.60 | 1.57 | 3.82 | -0.75 | 2.94 | 4.23 | 4.82 | 3.79 | 2.14 |
| OPM % | 2.92% | 1.94% | 2.63% | 0.92% | 2.79% | 2.29% | 4.46% | -0.84% | 3.16% | 4.76% | 4.31% | 2.97% | 1.82% |
| Other Income | 0.11 | 0.13 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.31 | 0.22 | 0.22 | 0.19 | 0.20 | 0.19 |
| Interest | 0.62 | 0.66 | 0.65 | 0.60 | 0.64 | 0.63 | 0.69 | 0.50 | 0.56 | 0.56 | 0.57 | 0.58 | 0.53 |
| Depreciation | 0.32 | 0.32 | 0.32 | 0.31 | 0.33 | 0.26 | 0.39 | 0.34 | 0.32 | 0.32 | 0.46 | 0.21 | 0.33 |
| Profit before tax | 1.63 | 0.62 | 1.65 | 0.06 | 1.75 | 0.80 | 2.86 | -1.28 | 2.28 | 3.57 | 3.98 | 3.20 | 1.47 |
| Tax % | 17.79% | 27.42% | 37.58% | 116.67% | 27.43% | 2.50% | 45.10% | -64.84% | 24.56% | 24.65% | 29.15% | 22.19% | 48.98% |
| Net Profit | 1.34 | 0.46 | 1.03 | -0.02 | 1.26 | 0.78 | 1.56 | -0.45 | 1.72 | 2.69 | 2.82 | 2.48 | 0.75 |
| EPS in Rs | 2.33 | 0.80 | 1.79 | -0.03 | 2.19 | 1.36 | 2.71 | -0.78 | 2.99 | 4.68 | 4.90 | 4.31 | 1.30 |
Last Updated: August 19, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Ambar Protein Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 117.27 Cr.. The value appears to be declining and may need further review. It has decreased from 127.81 Cr. (Mar 2025) to 117.27 Cr., marking a decrease of 10.54 Cr..
- For Expenses, as of Jun 2025, the value is 115.13 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 124.02 Cr. (Mar 2025) to 115.13 Cr., marking a decrease of 8.89 Cr..
- For Operating Profit, as of Jun 2025, the value is 2.14 Cr.. The value appears to be declining and may need further review. It has decreased from 3.79 Cr. (Mar 2025) to 2.14 Cr., marking a decrease of 1.65 Cr..
- For OPM %, as of Jun 2025, the value is 1.82%. The value appears to be declining and may need further review. It has decreased from 2.97% (Mar 2025) to 1.82%, marking a decrease of 1.15%.
- For Other Income, as of Jun 2025, the value is 0.19 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Mar 2025) to 0.19 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.58 Cr. (Mar 2025) to 0.53 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 0.33 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.21 Cr. (Mar 2025) to 0.33 Cr., marking an increase of 0.12 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.47 Cr.. The value appears to be declining and may need further review. It has decreased from 3.20 Cr. (Mar 2025) to 1.47 Cr., marking a decrease of 1.73 Cr..
- For Tax %, as of Jun 2025, the value is 48.98%. The value appears to be increasing, which may not be favorable. It has increased from 22.19% (Mar 2025) to 48.98%, marking an increase of 26.79%.
- For Net Profit, as of Jun 2025, the value is 0.75 Cr.. The value appears to be declining and may need further review. It has decreased from 2.48 Cr. (Mar 2025) to 0.75 Cr., marking a decrease of 1.73 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.30. The value appears to be declining and may need further review. It has decreased from 4.31 (Mar 2025) to 1.30, marking a decrease of 3.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 157 | 168 | 195 | 206 | 231 | 284 | 313 | 340 | 345 | 336 | 421 | 446 |
| Expenses | 159 | 155 | 167 | 193 | 203 | 227 | 278 | 305 | 330 | 338 | 328 | 406 | 431 |
| Operating Profit | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 8 | 9 | 7 | 7 | 16 | 15 |
| OPM % | 1% | 1% | 1% | 1% | 1% | 2% | 2% | 2% | 3% | 2% | 2% | 4% | 3% |
| Other Income | 0 | 1 | 0 | 1 | 1 | 0 | 0 | -0 | 1 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 2 | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 13 | 12 |
| Tax % | 0% | 0% | 36% | 2% | 27% | 28% | 55% | 13% | 25% | 29% | 24% | 26% | |
| Net Profit | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 3 | 4 | 3 | 3 | 10 | 9 |
| EPS in Rs | 0.14 | 2.70 | 1.51 | 4.19 | 3.74 | 3.53 | 2.17 | 6.00 | 7.74 | 4.89 | 5.48 | 16.78 | 15.19 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 100.00% | 0.00% | 0.00% | -50.00% | 200.00% | 33.33% | -25.00% | 0.00% | 233.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 150.00% | -100.00% | 0.00% | -50.00% | 250.00% | -166.67% | -58.33% | 25.00% | 233.33% |
Ambar Protein Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 50% |
| 3 Years: | 29% |
| TTM: | 142% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| 1 Year: | 127% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| Last Year: | 32% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: October 10, 2025, 3:25 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | -4 | -3 | -1 | 0 | 2 | 4 | 5 | 9 | 13 | 16 | 19 | 29 |
| Borrowings | 6 | 6 | 8 | 10 | 18 | 24 | 27 | 27 | 33 | 29 | 26 | 26 |
| Other Liabilities | 5 | 4 | 5 | 7 | 5 | 19 | 11 | 8 | 12 | 11 | 11 | 10 |
| Total Liabilities | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 |
| Fixed Assets | 4 | 4 | 6 | 6 | 6 | 7 | 22 | 21 | 21 | 20 | 19 | 18 |
| CWIP | 0 | 0 | 0 | 0 | 6 | 16 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8 | 9 | 12 | 17 | 19 | 31 | 27 | 29 | 44 | 42 | 42 | 51 |
| Total Assets | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 |
Below is a detailed analysis of the balance sheet data for Ambar Protein Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
- For Reserves, as of Mar 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2024) to 29.00 Cr., marking an increase of 10.00 Cr..
- For Borrowings, as of Mar 2025, the value is 26.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 26.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing). It has decreased from 11.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 1.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 71.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.00 Cr. (Mar 2024) to 71.00 Cr., marking an increase of 10.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2024) to 18.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 51.00 Cr., marking an increase of 9.00 Cr..
- For Total Assets, as of Mar 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2024) to 71.00 Cr., marking an increase of 10.00 Cr..
Notably, the Reserves (29.00 Cr.) exceed the Borrowings (26.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -4.00 | -6.00 | -7.00 | -15.00 | -20.00 | -21.00 | -19.00 | -24.00 | -22.00 | -19.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3 | 2 | 3 | 8 | 3 | 2 | 3 | 4 | 10 | 15 | 15 | 18 |
| Inventory Days | 11 | 12 | 18 | 19 | 16 | 37 | 20 | 22 | 32 | 23 | 24 | 20 |
| Days Payable | 13 | 10 | 11 | 9 | 6 | 10 | 3 | 5 | 9 | 7 | 8 | 3 |
| Cash Conversion Cycle | 1 | 4 | 10 | 18 | 13 | 29 | 19 | 21 | 33 | 30 | 31 | 34 |
| Working Capital Days | -8 | -8 | -4 | -1 | -4 | -9 | -8 | -2 | 3 | 4 | 6 | 12 |
| ROCE % | 8% | 28% | 18% | 22% | 17% | 13% | 15% | 18% | 18% | 13% | 13% | 28% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Diluted EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Cash EPS (Rs.) | 19.06 | 7.75 | 7.11 | 9.97 | 8.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Revenue From Operations / Share (Rs.) | 733.26 | 586.19 | 600.13 | 590.87 | 544.87 |
| PBDIT / Share (Rs.) | 28.89 | 13.72 | 13.50 | 17.18 | 13.61 |
| PBIT / Share (Rs.) | 26.61 | 11.43 | 11.29 | 14.95 | 11.52 |
| PBT / Share (Rs.) | 22.66 | 7.16 | 6.88 | 10.27 | 6.92 |
| Net Profit / Share (Rs.) | 16.78 | 5.47 | 4.89 | 7.74 | 6.00 |
| PBDIT Margin (%) | 3.93 | 2.34 | 2.25 | 2.90 | 2.49 |
| PBIT Margin (%) | 3.62 | 1.95 | 1.88 | 2.53 | 2.11 |
| PBT Margin (%) | 3.09 | 1.22 | 1.14 | 1.73 | 1.27 |
| Net Profit Margin (%) | 2.28 | 0.93 | 0.81 | 1.30 | 1.10 |
| Return on Networth / Equity (%) | 27.79 | 12.54 | 12.83 | 23.30 | 23.54 |
| Return on Capital Employeed (%) | 41.06 | 23.61 | 24.19 | 34.46 | 30.62 |
| Return On Assets (%) | 13.68 | 5.12 | 4.51 | 6.93 | 6.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.07 | 0.14 | 0.24 |
| Total Debt / Equity (X) | 0.74 | 1.02 | 1.34 | 1.72 | 1.86 |
| Asset Turnover Ratio (%) | 6.39 | 5.45 | 5.46 | 5.94 | 6.29 |
| Current Ratio (X) | 1.45 | 1.21 | 1.19 | 1.11 | 1.00 |
| Quick Ratio (X) | 0.83 | 0.61 | 0.63 | 0.42 | 0.39 |
| Inventory Turnover Ratio (X) | 20.84 | 16.08 | 13.93 | 14.65 | 18.92 |
| Interest Coverage Ratio (X) | 7.32 | 3.21 | 3.07 | 3.67 | 2.96 |
| Interest Coverage Ratio (Post Tax) (X) | 5.26 | 2.28 | 2.11 | 2.65 | 2.30 |
| Enterprise Value (Cr.) | 141.53 | 108.01 | 151.38 | 48.68 | 29.74 |
| EV / Net Operating Revenue (X) | 0.33 | 0.32 | 0.43 | 0.14 | 0.09 |
| EV / EBITDA (X) | 8.52 | 13.69 | 19.50 | 4.93 | 3.80 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| Price / BV (X) | 3.36 | 3.34 | 5.62 | 0.89 | 0.27 |
| Price / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| EarningsYield | 0.08 | 0.03 | 0.02 | 0.26 | 0.85 |
After reviewing the key financial ratios for Ambar Protein Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.06. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 19.06, marking an increase of 11.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 733.26. It has increased from 586.19 (Mar 24) to 733.26, marking an increase of 147.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.89. This value is within the healthy range. It has increased from 13.72 (Mar 24) to 28.89, marking an increase of 15.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.61. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 26.61, marking an increase of 15.18.
- For PBT / Share (Rs.), as of Mar 25, the value is 22.66. This value is within the healthy range. It has increased from 7.16 (Mar 24) to 22.66, marking an increase of 15.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For PBDIT Margin (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 10. It has increased from 2.34 (Mar 24) to 3.93, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.62, marking an increase of 1.67.
- For PBT Margin (%), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 10. It has increased from 1.22 (Mar 24) to 3.09, marking an increase of 1.87.
- For Net Profit Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 5. It has increased from 0.93 (Mar 24) to 2.28, marking an increase of 1.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.79. This value is within the healthy range. It has increased from 12.54 (Mar 24) to 27.79, marking an increase of 15.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 23.61 (Mar 24) to 41.06, marking an increase of 17.45.
- For Return On Assets (%), as of Mar 25, the value is 13.68. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 13.68, marking an increase of 8.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.74. This value is within the healthy range. It has decreased from 1.02 (Mar 24) to 0.74, marking a decrease of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 6.39. It has increased from 5.45 (Mar 24) to 6.39, marking an increase of 0.94.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.45, marking an increase of 0.24.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.83, marking an increase of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.84. This value exceeds the healthy maximum of 8. It has increased from 16.08 (Mar 24) to 20.84, marking an increase of 4.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.32. This value is within the healthy range. It has increased from 3.21 (Mar 24) to 7.32, marking an increase of 4.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.26. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 5.26, marking an increase of 2.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.53. It has increased from 108.01 (Mar 24) to 141.53, marking an increase of 33.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.33, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 8.52. This value is within the healthy range. It has decreased from 13.69 (Mar 24) to 8.52, marking a decrease of 5.17.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For Price / BV (X), as of Mar 25, the value is 3.36. This value exceeds the healthy maximum of 3. It has increased from 3.34 (Mar 24) to 3.36, marking an increase of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambar Protein Industries Ltd:
- Net Profit Margin: 2.28%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 41.06% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.79% (Industry Average ROE: 12.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.6 (Industry average Stock P/E: 340.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.74
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.28%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Block No. 351p2, 353p2 and 358, Panchratna Estate, Ahmedabad District Gujarat 382213 | ambarinv@gmail.com http://www.ambarprotein.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep C Khetani | Managing Director |
| Mr. Jayprakash J Vachhani | Whole Time Director |
| Mr. Shirishkumar D Patel | Director |
| Mr. Bharatbhai D Patel | Director |
| Mr. Dashrathbhai A Patel | Director |
| Mrs. Shobhanaben J Vachhani | Director |
| Mr. Gangaram Bhanjibhai Patel | Independent Director |
| Mr. Yogen Pranjivandas Patel | Independent Director |
| Mr. Narottam Chaturdas Tanna | Independent Director |
FAQ
What is the intrinsic value of Ambar Protein Industries Ltd?
Ambar Protein Industries Ltd's intrinsic value (as of 07 November 2025) is 354.00 which is 22.49% higher the current market price of 289.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 166 Cr. market cap, FY2025-2026 high/low of 433/168, reserves of ₹29 Cr, and liabilities of 71 Cr.
What is the Market Cap of Ambar Protein Industries Ltd?
The Market Cap of Ambar Protein Industries Ltd is 166 Cr..
What is the current Stock Price of Ambar Protein Industries Ltd as on 07 November 2025?
The current stock price of Ambar Protein Industries Ltd as on 07 November 2025 is 289.
What is the High / Low of Ambar Protein Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ambar Protein Industries Ltd stocks is 433/168.
What is the Stock P/E of Ambar Protein Industries Ltd?
The Stock P/E of Ambar Protein Industries Ltd is 20.6.
What is the Book Value of Ambar Protein Industries Ltd?
The Book Value of Ambar Protein Industries Ltd is 65.2.
What is the Dividend Yield of Ambar Protein Industries Ltd?
The Dividend Yield of Ambar Protein Industries Ltd is 0.00 %.
What is the ROCE of Ambar Protein Industries Ltd?
The ROCE of Ambar Protein Industries Ltd is 27.5 %.
What is the ROE of Ambar Protein Industries Ltd?
The ROE of Ambar Protein Industries Ltd is 32.3 %.
What is the Face Value of Ambar Protein Industries Ltd?
The Face Value of Ambar Protein Industries Ltd is 10.0.